TRV734

TRV734 is an experimental drug candidate that is being developed for the treatment of pain. It is a selective agonist for the mu opioid receptor, which is the primary target of most opioid drugs. TRV734 is being developed by Trevena, a pharmaceutical company based in the United States.

History

TRV734 was first synthesized and characterized by scientists at Trevena. The drug is part of a new class of opioids that are designed to provide pain relief without the side effects associated with traditional opioids. This is achieved by selectively targeting the mu opioid receptor in a way that avoids the activation of the beta-arrestin pathway, which is believed to be responsible for many of the side effects of opioids.

Pharmacology

TRV734 is a selective agonist for the mu opioid receptor. This means that it binds to this receptor and activates it, leading to pain relief. However, unlike traditional opioids, TRV734 does not activate the beta-arrestin pathway. This is believed to result in fewer side effects, such as respiratory depression and constipation, which are common with traditional opioids.

Clinical trials

As of 2021, TRV734 is in the early stages of clinical development. It has been tested in phase 1 clinical trials, which are designed to assess the safety and tolerability of a new drug. The results of these trials have not yet been published.

See also

• Opioid
• Mu opioid receptor
• Beta-arrestin pathway
• Trevena (company)

References

TRV734 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia